We similarly observed an increase in the mean CCNE1 copy number when considering only breast, ovarian, and endometrial cancers with and without a BRD4 focal deletion (7.1 vs. 4.1; p = 0.0002; Wilcoxon rank-sum test; Figure 1C). Here, BRD4 is linked to endometrial cancer.